Featured/ YMAB/ 08/05/2025 · 8:53 AM SERB Acquires Y-mAbs: Rare Oncology Expansion SERB Pharmaceuticals acquires Y-mAbs for $412M, gaining DANYELZA, an FDA-approved treatment for high-risk neuroblastoma, enhancing rare oncology portfolio.
